Navigation Links
Immune Design Corp. and Sanofi-Aventis Announce Research Collaboration
Date:10/26/2011

SEATTLE, Oct. 26, 2011 /PRNewswire/ -- Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease, cancer and allergy, announced today that it has entered into an early-stage research collaboration with Sanofi-Aventis to investigate the use of IDC's Glucopyranosyl Lipid Adjuvant (GLA) technology, a toll–like receptor 4 (TLR-4) agonist, in the field of allergy.

(Logo: http://photos.prnewswire.com/prnh/20111018/SF88252LOGO)

"We are excited to form this relationship with Sanofi," noted IDC CEO Carlos Paya, MD, Ph.D.  "The application of next-generation TLR-4 agonists able to shape the immune response in allergic disease has enormous therapeutic potential.  Our initial collaboration has the strong possibility to lead to a broader development focused partnership with Sanofi in the near future."

Under the agreement, IDC will provide access to the GLA technology, allowing Sanofi the ability to evaluate the biological and immunological properties of this TLR-4 agonist in vitro and in allergy disease models, and will be granted an option to select lead candidates for further development.  The terms have not been disclosed.    

IDC has advanced the GLA technology into early clinical stage development.  This technology can be used to promote optimal activation of human dendritic cells, has demonstrated compatibility with many antigens, and has a well-established safety profile to date.

Additional information can be found on the company's website at www.immunedesign.com.

Media Relations

Immune Design Corp.
Cassie Ostrander
Phone:  206-826-7901
E-mail:  media@immunedesign.com


'/>"/>
SOURCE Immune Design Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Immune Design Corp. Appoints Guy F. Cipriani as Chief Business Officer
2. Alcohol-related behavior changes -- blame your immune system
3. Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy
4. New HIV vaccine approach targets desirable immune cells
5. David H. Murdock Research Institute Assumes Control of the Immune Tolerance Institute and Establishes a State of the Art Human Immune Monitoring Laboratory for Biomarker Discovery and Development
6. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
7. UCLA scientists discover new way to wake up the immune system using nano vaults to deliver drugs
8. Amgen and Xencor Enter Option Deal to Co-Develop Xencors Novel Antibody for Autoimmune Diseases
9. NIH scientists show how anthrax bacteria impair immune response
10. Immune Design Grants Adjuvant License to MedImmune
11. Adaptive TCR Launches the immunoSEQâ„¢ Product Line - Visualizing the Immune System With Next-Generation Sequencing.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ... and biotechnology companies dedicated to collaboratively developing improved chemistry, manufacturing and control ... vendor-supported, portable online UHPLC, with robust, probe-based sampling. , Online liquid ...
(Date:12/2/2016)... --  SurePure, Inc. (OTCQB: SURP) a global leader ... concluded an agreement with Tamarack Biotics under which Tamarack ... acquire units of the Company,s patented photopurification technology with ... Concurrently with the option, SurePure has entered ... seek regulatory approvals in the United States ...
(Date:12/2/2016)... 2, 2016 /PRNewswire/ - bioLytical Laboratories, a world leader in rapid infectious disease tests, ... Pharmaceutical Association members. (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ... ... , , ... Pharmaceutical Association (KPA) to introduce the INSTI HIV Self Test to 350 pharmacy representatives ...
(Date:11/30/2016)... , Nov. 30, 2016  GenomOncology today announced the appointment ... of Medical Affairs.  Dr. Coleman will oversee ... company,s proprietary knowledge-enabled platform. The GenomOncology software suite empowers molecular ... sequencing data and clinical decision support, from quality control through ... , , ...
Breaking Biology Technology:
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/14/2016)... Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), ... in challenging operating environments, announced its results for the ... a conference call to discuss these results on November ... Key Recent Accomplishments ... acquire Vislink Communication Systems. The purchase is expected to ...
Breaking Biology News(10 mins):